August 2021
3:12 AM IST
News Headlines
Bajaj Auto July sales jumps 44 pc in Jul        Pegasus issue: SC to hear on Aug 5 pleas seeking probe into snooping allegations        Dutee finishes last in her 200m heat race, fails to qualify for semifinals at Olympics        Pakistan reports spike in new COVID-19 cases        Mexico's referendum on trying ex-presidents falls short        Berlin protesters decry coronavirus measures; 600 detained        Brave Indian women create history, enter maiden Olympic hockey semifinals        Tokyo Olympics: Badminton star P V Sindhu scripts history on Super Sunday        India beat South Africa 4-3 to keep QF hopes alive in Olympic women's hockey        World No.1 Panghal's Olympic campaign ends with shocking loss to Colombian Martinez        COVID-19: India records 41,649 fresh cases, 593 more fatalities        TREMOR        Das knocks out Olympic champion in Tokyo, joins wife Deepika in last-16        Air India sold its 115 properties for Rs 738 crore since 2015: Govt        Researchers Develop Variants Of More Potent, Stable Nanobodies To Fight SARS-CoV-2        Assam, Mizoram trade barbs over deployment of security forces at interstate border        HC rejects plea to reassess minority status of Christians, Muslims in Kerala        Govt hiding on Pegasus issue, responsible for Parliament logjam: Congress        True legend of Indian badminton: tributes pour in after legendary Nandu Natekar dies        Tendulkar helps farmer's daughter to pursue dream of becoming doctor        
Home   | Main News   | Kerala  | National   | International  | Business   | Sports   | Entertainment   | Columns   | Offbeat   | About Deepika 
International News
Taiwan's push to shortcut vaccine approval sparks debate
Taipei (Taiwan): At the end of May, Chen Pei-jer, a member of an expert committee in Taiwan to evaluate COVID-19 vaccines for use on the island, resigned.

Chen's resignation came after he learned that Taiwan's Food and Drug Administration planned to take a regulatory shortcut in approving two vaccines being developed in Taiwan.

The shortcut would allow the shots to be given to people for emergency use before the vaccines have finished the final stage of testing.

The proposed shortcut comes as Taiwan scrambles to get vaccines amid its worst outbreak of the pandemic, and has also recorded its first cases of the highly contagious delta variant originally found in India.

Supporters say the shortcut is needed because Taiwan is in a real crunch, and they argue that the move could soon become more common worldwide. That's because as more vaccines roll out, it's getting increasingly difficult to conduct the usual tests of a vaccine's efficacy.

But as Chen's resignation shows, the proposed move has also raised concerns about the risks, chiefly regarding whether people might be given a vaccine that ultimately is shown not to work.

This is a shortcut, and this has to do with President Tsai (Ing-wen) we don't have enough vaccines, and the ruling party is very anxious, said Chen, referring to the president's remarks in May saying the first batch of domestically made vaccines would be ready in July.

Those remarks were viewed by some as putting pressure on regulators before interim data was even analyzed.

Tsai has since revised her comments to say July is a goal, and she hopes the first batch will be ready by then.

Chen, a member of Taiwan's Academia Sinica, a top government-backed research institute, said he resigned because he felt politics had interfered with what should be an independent, scientific process.

He also felt the proposed shortcut didn't have enough scientific evidence or global recognition to justify it.

Vaccines that are in use globally have gone through a final stage of clinical trials large, carefully designed studies in which the vaccine is given to people who are monitored against a non-vaccinated group to see if the former are more protected from the disease.

Taiwan's shortcut would give emergency-use approval to two vaccines before those studies, although the two shots have gone through first and mid-stage testing just like other vaccines.

Instead, the makers would have to demonstrate that the vaccines generate antibodies against COVID-19 at the same level as the AstraZeneca vaccine, which has already been approved for use in Taiwan.

There is growing evidence that the level of antibodies in a person's blood means a certain level of protection from COVID-19, but it is not definitive.

Taiwanese experts who support the approach say there's sufficient evidence and urgency as the island battles an ongoing outbreak.

It has vaccinated just 4 per cent of its population of 24 million people and has struggled to get doses because of a global supply crunch.

As of Sunday, the COVID-19 death toll has jumped to 686 people, from only about a dozen prior to the current outbreak.

Now with COVID-19 you can't do it that way, where you wait until a randomized clinical trial people are dying, said Ho Mei-Shang, a vaccine expert in Taiwan who has also worked for the US Centers for Disease Control and Prevention. In the short term we are not going to get our sufficient amount of vaccines.

At least three countries have allowed early use of vaccines even without the final testing. Russia and China started giving shots last year before finishing their last stage of trials, leading to global criticism. India's early approval of a vaccine sparked anger and mistrust in its medical community.

Elsewhere, most countries and the WHO have only granted approval after the final study. Authorities like the US FDA and the European EMEA, which are often looked to globally for their regulatory decisions, have said they would approve vaccines based on antibody data if an already approved vaccine is being redeveloped for a variant. They have not said the same for a new vaccine.

The UK is looking at possibly doing the same as Taiwan.

The British government's National Institute for Health Research is testing a new vaccine developed by French company Valneva to see if it generates antibodies comparable to the AstraZeneca vaccine in 4,000 volunteers.

If the approach works in the UK and Taiwan, it could be a life-saver for vaccine developers and countries badly in need of doses.

As more and more people get access to vaccines, the ethics and difficulty of doing one of these trials in which one group gets the vaccine and the other gets a placebo becomes more complex.

Who would accept a placebo if they knew they can get a vaccine? said Jerome Kim, the head of the International Vaccine Institute, a UN agency.

Giving a volunteer a placebo and subjecting them to the risk of possibly getting infected when proven vaccines are available may be considered unethical by some regulators, he added.

Taiwanese regulators have said they would grant emergency use approval to two vaccines in development, if they pass the antibody test.

One is being developed by Taiwanese firm Medigen, the other by an American company Vaxxinity, which is testing the vaccine in Taiwan.

Medigen said this month that it had submitted an application for emergency use to Taiwan's FDA and planned to conduct the third and final stage clinical trials after approval.

The reasons are the difficulty to execute the conventional phase 3 study and also the ethical challenge, the company said in an email response to questions.

Vaxxinity announced in June they signed a deal of 1 million doses with Paraguay, one of Taiwan's remaining diplomatic allies, to be delivered once the Taiwanese FDA gives their vaccine emergency-use authorization. The company is finishing mid-stage testing.

Taiwan has been considering taking this path since at least last fall, when it seemed they would be unable to do the last stage of clinical trials because the virus was under control and people weren't getting infected anyway.

It doesn't mean it's an unusual decision or a crazy decision, it's relevant to circumstances, said said Nikolai Petrovsky, a vaccine expert at Flinders University in Australia.

Opposition parties in Taiwan have seized on the issue, criticizing the government for pushing ahead with a standard not yet accepted globally, and wondering if the government was playing favorites with domestic companies.

K. Arnold Chan, a clinical trials expert at National Taiwan University and a member of the expert panel in Taiwan, said that there are lot of uncertainties with vaccine development.

He pointed to CureVac, a German company, which recently announced disappointing results from a large late-stage study for its COVID-19 vaccine of that found efficacy was below 50 per cent.

You can imagine the ramifications that someone is thought to be protected, but is not and it's not stopping the chain of infection," Chan said. The risk is we spent a lot of money, (and) we purchased a very expensive placebo.

Pakistan reports spike in new COVID-19 cases
Mexico's referendum on trying ex-presidents falls short
Berlin protesters decry coronavirus measures; 600 detained
Researchers Develop Variants Of More Potent, Stable Nanobodies To Fight SARS-CoV-2
The Taliban: what could its return to power mean for Afghanistan?
Biden says US combat mission in Iraq to conclude by year end
Pak PM Khan's party wins most seats in PoK legislative elections marred by irregularities, violence
At least 6 killed in 20-car pileup in Utah during sandstorm
Europe's summer tourism outlook dimmed by variants, rules
China sends supplies to flooded area, rebuilds barriers
US hospital donates COVID-related medical equipment to India
US carried out airstrikes in Afghanistan: Pentagon
Australia wants to change AstraZeneca advice
China rolls out 600 km/h high-speed maglev train
Japanese PM Suga says world should see safe Olympics staged
Probe: Journalists, activists among firm's spyware targets
Look forward to working closely with PM Modi to strengthen Nepal-India ties: Deuba
ICC welcomes Mongolia, Tajikistan and Switzerland as new members
Biden to host Iraq's prime minister at White House on July 26
Largest wildfire in Oregon expands further; new evacuations
George Clooney says Capitol attack put Trump family 'into the dustbin of history'
 Los Angeles: Hollywood star George Clooney has condemned the attack on the Capitol Hill in the US by  
'Mean Girls' won't be returning to Broadway
Ian McKellan is 'happy' Elliot Page came out as transgender
A R Rahman thanks fans for support during 'difficult times'
HC rejects plea to reassess minority status of Christians, Muslims in Kerala
 Kochi: The Kerala High Court on Thursday said merely because there are a few rich people among the m
COVID-19: Over 4.5L vaccinations on Saturday, more than 16 lakh jabs this week in Kerala
Curbs tightened in Kerala following increase in COVID TPR
UDF walks out of Kerala Assembly over allegations against Forest Minister
Pegasus issue: SC to hear on Aug 5 pleas seeking probe into snooping allegations
 New Delhi, Aug 1 (PTI) The Supreme Court is scheduled to hear on August 5 the pleas, including the o
Assam, Mizoram trade barbs over deployment of security forces at interstate border
48% parents not willing to send their kids to schools till they get Covid vaccines: Survey
Will depend on situation, no problem if someone else leads: Mamata Banerjee on being face of Oppn
Untitled Page
Rashtra Deepika LTD
Copyright @ 2021 , Rashtra Deepika Ltd.